Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Recruiting Phase 3 Interventional

Pridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALS

ClinicalTrials.gov ID: NCT07322003

Public ClinicalTrials.gov record NCT07322003. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 17, 2026, 10:14 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Pridopidine in Participants With Amyotrophic Lateral Sclerosis

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The goal of this clinical trial is to learn if the drug pridopidine works to treat amyotrophic lateral sclerosis in adults. It will also help to learn about the safety of pridopidine. The main question it aims to answer is: Does pridopidine slow disease progression of ALS? Researchers will compare pridopidine to a placebo (a look-alike substance that contains no drug) to see if pridopidine works to treat ALS. Participants will: Take pridopidine or a placebo by mouth every day for 48 weeks. Afterwards, all participants will take pridopidine for another 48 weeks. Visit the clinic once every 1-3 months for checkups and tests

Study identification

NCT ID
NCT07322003
Recruitment status
Recruiting
Study type
Interventional
Phase
Phase 3
Lead sponsor
Prilenia
Industry
Enrollment
500 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years to 80 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jan 31, 2026
Primary completion
Feb 29, 2028
Completion
Feb 28, 2029
Last update posted
Sep 14, 2026

2026 – 2029

United States locations

U.S. sites
18
U.S. states
15
U.S. cities
17
Facility City State ZIP Site status
Barrow Neurological Institute Phoenix Arizona 85013 Recruiting
California Pacific Medical Center San Francisco California 94109 Recruiting
University of Colorado CU Anschutz Neurology Aurora Colorado 80045 Recruiting
Mayo Clinic Jacksonville Florida 32224 Recruiting
University of South Florida Tampa Florida 33612 Recruiting
Emory University Atlanta Georgia 30322 Recruiting
Northwestern University Chicago Illinois 60611 Recruiting
University of Kansas Fairway Kansas 66205 Recruiting
Johns Hopkins University Baltimore Maryland 21205 Recruiting
Sean M. Healey & AMG Center for ALS Boston Massachusetts 02114 Recruiting
Washington University St Louis Missouri 63110 Recruiting
Somnos Clinical Research Lincoln Nebraska 68506 Recruiting
Eleanor and Lou Gehrig ALS Center at Columbia University New York New York 10032 Recruiting
Neuroscience Department at LKSM at Temple University Philadelphia Pennsylvania 19140 Recruiting
Texas Neurology Dallas Texas 75206 Recruiting
Baylor College of Medicine; McNair Medical Campus Houston Texas 77030 Recruiting
Swedish Medical Center Seattle Washington 98122 Recruiting
University of Washington Seattle Washington 98195 Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 37 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT07322003, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Sep 14, 2026 · Synced Sep 17, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT07322003 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →